ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

July 8, 2020

Neuropathological profile of long duration amyotrophic lateral sclerosis in military Veterans

Brain Pathology
Keith R SpencerThor D Stein
July 7, 2020
Open Access

Association Between Vitamins and Amyotrophic Lateral Sclerosis: A Center-Based Survey in Mainland China

Frontiers in Neurology
Mengli WangJunling Wang
July 6, 2020
Open Access

C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression

Nature Communications
Yu SunJunjie U Guo
July 9, 2020

Targeted next-generation sequencing study in familial ALS-FTD Portuguese patients negative for C9orf72 HRE

Journal of Neurology
Marta GromichoMamede de Carvalho
July 9, 2020

Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

Journal of Cardiovascular Pharmacology
Zoltán PappPiero Pollesello
July 9, 2020
Review

Modern approaches in gene therapy of motor neuron diseases

Medicinal Research Reviews
Maria Zakharova
July 6, 2020
Review

Poly adenosine diphosphate-ribosylation and neurodegenerative diseases

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Yi Wang, Yunbi Lu
July 8, 2020

Safety and efficacy of levosimendan in patients with cardiac amyloidosis

European Journal of Internal Medicine
Alberto AimoMichele Emdin
July 9, 2020
Open Access

A proof-of-concept study of extracting patient histories for rare/intractable diseases from social media

Genomics & Informatics
Atsuko Yamaguchi, Núria Queralt-Rosinach
July 9, 2020
Open Access

Base editing with high efficiency in allotetraploid oilseed rape by A3A-PBE base editing system

Plant Biotechnology Journal
Hongtao ChengQiong Hu
July 9, 2020

Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis

Aging
Jordan M WilkinsClaudia F Lucchinetti
July 9, 2020

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

The New England Journal of Medicine
Timothy MillerToby A Ferguson
July 7, 2020
Review

ALS, a cellular whodunit on motor neuron degeneration

Molecular and Cellular Neurosciences
Peter Karagiannis, Haruhisa Inoue
July 8, 2020
Review
Open Access

Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine
Mina KaramiJosé P S Henriques
July 9, 2020
Review
Open Access

Neurovascular Inflammaging in Health and Disease

Cells
Ádám MészárosIstván A Krizbai
July 8, 2020

Neurology Grand Rounds Complications from "Stem Cell Tourism" in Neurology

Annals of Neurology
Katherine JulianJaime Imitola
July 9, 2020
Open Access

Reply to: Early white matter changes on diffusion tensor imaging in amyotrophic lateral sclerosis

Annals of Clinical and Translational Neurology
Matt C GabelP Nigel Leigh
July 9, 2020

Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis

Journal of Neurology
Christian LunettaJonica Campolo

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

Aging Epidemiology

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

© 2020 Meta ULC. All rights reserved
/feed-previews/als-therapies/70cf9704-ab72-4a54-b1b1-b2e7d895a2cc